R Reed1, M Mehra2, S Kirshblum3, D Maier4, D Lammertse5, A Blight6, R Rupp7, L Jones8, R Abel9, N Weidner7, A Curt10, J Steeves1,11. 1. ICORD, University of British Columbia and Vancouver General Hospital, Blusson Spinal Cord Centre, Vancouver, British Columbia, Canada. 2. Tigermed-MacroStat LLC, Gaithersburg, MD, USA. 3. Kessler Institute for Rehabilitation and Rutgers New Jersey Medical School, West Orange, NJ, USA. 4. Trauma Center Murnau, Murnau, Germany. 5. Craig Hospital, Englewood, CO, USA. 6. Acorda Therapeutics Inc., Hawthorne, NY, USA. 7. Spinal Cord Injury Center, Heidelberg University Hospital, Heidelberg, Germany. 8. Craig H. Neilsen Foundation, Encino, CA, USA. 9. Trauma Center Bayreuth, Bayreuth, Germany. 10. Spinal Cord Injury Center, University Hospital Balgrist, University of Zurich, Zurich, Switzerland. 11. SCOPE, C/O ASIA Central Office, Richmond, VA, USA.
Abstract
STUDY DESIGN: Retrospective statistical analysis of database. OBJECTIVE: Spinal cord injury (SCI) clinical trials are challenged to enroll participants, and early trial outcomes have often been equivocal. We hypothesized that a specifically designed novel true linear interval-scaled outcome measure targeted to simultaneously track a broad range of SCI will enable more inclusive enrollment of participants and valid comparisons of functional changes after SCI. METHODS: To define a single SCI measurement framework, we used items from existing measures. To evaluate linearity and validity of the measure, we used rigorous psychometric Rasch analysis on two data sets from over 2500 traumatic SCI participants (all levels and severities of SCI) within the EMSCI (European Multicenter study about SCI) database. RESULTS: Volitional performance was found to be the unidimensional construct that would detect and track a treatment effect from a central nervous system-directed therapeutic. Along with early evidence for voluntary neurological control of upper-extremity muscle contractions, volitional performance is best described by goal-directed activities of daily living that are increasingly difficult to re-acquire when activity within more caudal spinal segments is required. Validity of the Spinal Cord Ability Ruler (SCAR) as a linear interval construct was confirmed with Rasch analysis. All measurement items were properly ordered, as well as being precise and stable across clinically relevant groups. Only 5/24 items had some misfit. Targeting was excellent over time after SCI, with few gaps and only modest floor and ceiling effects (3% each). CONCLUSIONS: SCAR is a quantitative linear measure of volitional performance across an inclusive range of tetraplegic and paraplegic SCI.
STUDY DESIGN: Retrospective statistical analysis of database. OBJECTIVE:Spinal cord injury (SCI) clinical trials are challenged to enroll participants, and early trial outcomes have often been equivocal. We hypothesized that a specifically designed novel true linear interval-scaled outcome measure targeted to simultaneously track a broad range of SCI will enable more inclusive enrollment of participants and valid comparisons of functional changes after SCI. METHODS: To define a single SCI measurement framework, we used items from existing measures. To evaluate linearity and validity of the measure, we used rigorous psychometric Rasch analysis on two data sets from over 2500 traumatic SCIparticipants (all levels and severities of SCI) within the EMSCI (European Multicenter study about SCI) database. RESULTS: Volitional performance was found to be the unidimensional construct that would detect and track a treatment effect from a central nervous system-directed therapeutic. Along with early evidence for voluntary neurological control of upper-extremity muscle contractions, volitional performance is best described by goal-directed activities of daily living that are increasingly difficult to re-acquire when activity within more caudal spinal segments is required. Validity of the Spinal Cord Ability Ruler (SCAR) as a linear interval construct was confirmed with Rasch analysis. All measurement items were properly ordered, as well as being precise and stable across clinically relevant groups. Only 5/24 items had some misfit. Targeting was excellent over time after SCI, with few gaps and only modest floor and ceiling effects (3% each). CONCLUSIONS: SCAR is a quantitative linear measure of volitional performance across an inclusive range of tetraplegic and paraplegic SCI.
Authors: Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring Journal: Value Health Date: 2011-10-13 Impact factor: 5.725
Authors: J D Steeves; D Lammertse; A Curt; J W Fawcett; M H Tuszynski; J F Ditunno; P H Ellaway; M G Fehlings; J D Guest; N Kleitman; P F Bartlett; A R Blight; V Dietz; B H Dobkin; R Grossman; D Short; M Nakamura; W P Coleman; M Gaviria; A Privat Journal: Spinal Cord Date: 2006-12-19 Impact factor: 2.772
Authors: V Bluvshtein; L Front; M Itzkovich; Y Benjamini; T Galili; I Gelernter; E Aidinoff; J Hart; L Tesio; F Biering-Sorensen; C Weeks; M T Laramee; C Craven; S L Hitzig; E Glaser; G Zeilig; S Aito; G Scivoletto; M Mecci; R J Chadwick; W S El Masry; A Osman; C A Glass; P Silva; B M Soni; B P Gardner; G Savic; E M Bergström; A Catz Journal: Spinal Cord Date: 2011-08-02 Impact factor: 2.772
Authors: Steven C Kirshblum; William Waring; Fin Biering-Sorensen; Stephen P Burns; Mark Johansen; Mary Schmidt-Read; William Donovan; Daniel Graves; Amit Jha; Linda Jones; M J Mulcahey; Andrei Krassioukov Journal: J Spinal Cord Med Date: 2011-11 Impact factor: 1.985
Authors: M Itzkovich; M Tripolski; G Zeilig; H Ring; N Rosentul; J Ronen; R Spasser; R Gepstein; A Catz Journal: Spinal Cord Date: 2002-08 Impact factor: 2.772
Authors: X Wu; J Liu; L G Tanadini; D P Lammertse; A R Blight; John L K Kramer; G Scivoletto; L Jones; S Kirshblum; R Abel; J Fawcett; E Field-Fote; J Guest; B Levinson; D Maier; K Tansey; N Weidner; W G Tetzlaff; T Hothorn; A Curt; J D Steeves Journal: Spinal Cord Date: 2014-12-16 Impact factor: 2.772
Authors: Andrew R Blight; Jane Hsieh; Armin Curt; James W Fawcett; James D Guest; Naomi Kleitman; Shekar N Kurpad; Brian K Kwon; Daniel P Lammertse; Norbert Weidner; John D Steeves Journal: Spinal Cord Date: 2019-04-08 Impact factor: 2.772
Authors: Linda A T Jones; Anne Bryden; Tracey L Wheeler; Keith E Tansey; Kim D Anderson; Michael S Beattie; Andrew Blight; Armin Curt; Edelle Field-Fote; James D Guest; Jane Hseih; Lyn B Jakeman; Sukhvinder Kalsi-Ryan; Laura Krisa; Daniel P Lammertse; Benjamin Leiby; Ralph Marino; Jan M Schwab; Giorgio Scivoletto; David S Tulsky; Ed Wirth; José Zariffa; Naomi Kleitman; Mary Jane Mulcahey; John D Steeves Journal: Spinal Cord Date: 2017-12-28 Impact factor: 2.772
Authors: Marc Bolliger; Andrew R Blight; Edelle C Field-Fote; Kristin Musselman; Serge Rossignol; Dorothy Barthélemy; Laurent Bouyer; Milos R Popovic; Jan M Schwab; Michael L Boninger; Keith E Tansey; Giorgio Scivoletto; Naomi Kleitman; Linda A T Jones; Dany H Gagnon; Sylvie Nadeau; Dirk Haupt; Lea Awai; Chris S Easthope; Björn Zörner; Ruediger Rupp; Dan Lammertse; Armin Curt; John Steeves Journal: Spinal Cord Date: 2018-04-27 Impact factor: 2.772